Skip to main content
You're browsing a read-only preview with shortened excerpts. Unlock full access

Clinical trial preview

A Randomized, Double-blind, Sham-controlled Pivotal Study of Sensory Stimulation in Subjects With Alzheimer's Disease (HOPE Study)

ClinicalTrials.gov · April 18, 2026

Preview

Phase 3 trial of Cognito Therapeutics' Spectris wearable (40Hz gamma light and sound, 1 hour/day) in 550 early Alzheimer's patients over 18 months. Primary endpoint: CDR-SB cognitive score change.

The complete summary, “why it matters” analysis and the original source link are available to members.

AlzheimersBCINeurostimulationPhase 3